Platinum Hypersensitivity
Showing 1 - 25 of 2,439
Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)
Not yet recruiting
- Recurrent Ovarian Cancer
-
Pittsburgh, PennsylvaniaMagee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed
Completed
- Ovarian Neoplasm
- +4 more
- (no location specified)
Aug 22, 2022
Platinum-Sensitive Biliary Tract Cancer Trial (Cisplatin, Gemcitabine, Oxaliplatin)
Withdrawn
- Platinum-Sensitive Biliary Tract Cancer
- Cisplatin
- +4 more
- (no location specified)
May 27, 2022
Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer Trial in Los Angeles (Simvastatin 40mg)
Recruiting
- Recurrent Ovarian Cancer
- Platinum-sensitive Ovarian Cancer
- Simvastatin 40mg
-
Los Angeles, CaliforniaCedars Sinai Medical Center
Apr 21, 2022
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)
Not yet recruiting
- High Grade Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine
- Carboplatin
- (no location specified)
Jul 11, 2022
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)
Recruiting
- Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine plus Bevacizumab
- Bevacizumab
-
New Orleans, Louisiana
- +3 more
Dec 16, 2022
Hormone Sensitive Metastatic Prostate Cancer, DNA Damage Repair Deficiency, Chemo Effect Trial in Nanjing (Docetaxel,
Recruiting
- Hormone Sensitive Metastatic Prostate Cancer
- +3 more
- Docetaxel
- +2 more
-
Nanjing, Jiangsu, ChinaDepartment of Urology, Drum Tower Hospital, Medical School of Na
Jul 13, 2022
Immediate Hypersensitivity Reactions to Platinum Salts in
Recruiting
- Drug Allergy
- no intervention
-
Nancy, Vandoeuvre-Lès-Nancy, FranceCHRU Nancy
Jun 4, 2021
Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemo, Platinum Sensitive Trial in China,
Active, not recruiting
- Relapsed Ovarian Cancer
- +2 more
- Olaparib 300mg tablets
-
Beijing, China
- +24 more
Dec 5, 2022
Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV Trial in Seoul (Oregovomab, Bevacizumab,
Recruiting
- Ovarian Cancer by FIGO Stage
- +2 more
- Oregovomab
- +3 more
-
Daegu, Korea, Republic of
- +5 more
Oct 20, 2022
Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)
Terminated
- Platinum Sensitive Ovarian Cancer
- Ovarian Cancer
- FRα peptide plus Adjuvant (GM-CSF)
- Adjuvant (GM-CSF) Alone
-
Birmingham, Alabama
- +17 more
Nov 21, 2022
Small Cell Lung Cancer, Platinum-Sensitive Lung Small Cell Carcinoma, Extensive-stage Small-cell Lung Cancer Trial in Bordeaux
Not yet recruiting
- Small Cell Lung Cancer
- +2 more
- Association of lurbinectedin and durvalumab
- Association of carboplatin and etoposide
-
Bordeaux, FranceInstitut Bergonié
Oct 5, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Active, not recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +11 more
- Aldesleukin
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 13, 2022
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer Trial in France (OSE2101, Pembrolizumab 25 MG/ML [Keytruda])
Recruiting
- Platinum-sensitive Ovarian Cancer
- Relapsed Ovarian Cancer
- OSE2101
- Pembrolizumab 25 MG/ML [Keytruda]
-
Angers, France
- +27 more
Jul 25, 2022
Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor Trial in Seoul
Recruiting
- Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
-
Seoul, Korea, Republic ofYonsei University College of Medicine
Jul 6, 2021
Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer Trial in Seoul (Olaparib-Pembrolizumab-Bevacizumab)
Enrolling by invitation
- Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer
-
Seoul, Korea, Republic ofYonsei Severance Hospital
Apr 14, 2021
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma Trial in United States (Pazopanib, Doxil)
Terminated
- Ovarian Cancer
- +2 more
-
Fort Myers, Florida
- +3 more
Oct 4, 2021
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial
Active, not recruiting
- Fallopian Tube Endometrioid Tumor
- +13 more
- Olaparib
- Tremelimumab
-
Orange, California
- +19 more
Jan 10, 2023
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Cambridge (Upifitimab rilsodotin,
Recruiting
- High Grade Serous Ovarian Cancer
- +2 more
- Upifitimab rilsodotin
- Placebo
-
Phoenix, Arizona
- +40 more
Jan 25, 2023
Ovarian Cancer Trial in Worldwide (AZD2281, matching )
Active, not recruiting
- Ovarian Cancer
- AZD2281
- matching placebo
-
Berkeley, California
- +73 more
Dec 19, 2022
Ovarian Cancer Recurrent Trial in Czechia (DCVAC/OvCa, Standard of Care Chemotherapy)
Completed
- Ovarian Cancer Recurrent
- DCVAC/OvCa
- Standard of Care Chemotherapy
-
Brno, Czechia
- +7 more
Apr 20, 2021
Urothelial Bladder Cancer, Gastric Adenocarcinoma, Gastro-oesophageal Adenocarcinoma Trial (Dostarlimab, Niraparib)
Not yet recruiting
- Urothelial Bladder Cancer
- +6 more
- (no location specified)
Feb 26, 2021
BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer Trial in Napoli (Olaparib tablets)
Recruiting
- BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
- Olaparib tablets
-
Napoli, ItalyIstituto Nazionale dei Tumori , Oncologia Medica - Dipartimento
Mar 3, 2021
Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma Trial in United
Active, not recruiting
- Metastatic Fallopian Tube Carcinoma
- +11 more
- Berzosertib
- +4 more
-
Phoenix, Arizona
- +13 more
Dec 2, 2022